DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06824051

CompletedPhase 1

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

4

Recruiting sites

—

Enrollment

120

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Visceral fat, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06824051
Org study ID27352
Secondary IDJ2A-MC-GZPQEli Lilly and Company

Timeline

Milestones

Study first posted2025-02-13actual
Study start2025-02-17actual
Primary completion2026-01-26actual
Study completion2026-01-26actual
Last update posted2026-02-25actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have a Body Mass Index (BMI)
–≥30.0 kilograms per square meter (kg/m2), or
–≥27.0 kg/m2 with comorbidities

Exclusion criteria

•Have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
•Have an unstable body weight within 90 days prior to screening
•Have acute or chronic hepatitis
•Are taking other medications or alternative remedies to manage weight loss

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Cardiometabolic biomarkers
2
Other (unclassified)
2
Patient-reported / QoL
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Percent Change from Baseline in Visceral Adipose Tissue (VAT)

Time frame:Baseline, Week 36

Visceral fat, change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 36

Body weight, % change

percent change from baseline, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Percent Change from Baseline in Fasting Total Cholesterol

Time frame:Baseline, Week 36

Total cholesterol, change

percent change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)

Time frame:Baseline, Week 36

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Change from Baseline in International Physical Activity Questionnaire-Long Form (IPAQ-L) Scores

Time frame:Baseline, Week 36

change from baseline, improvement

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Percent Change from Baseline in Energy Intake

Time frame:Baseline, Week 36

percent change from baseline, improvement

Secondary/protocol endpoint/low confidence

Percent Change from Baseline in Appetite

Time frame:Baseline, Week 36

percent change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.